High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
89.91M
-76.89%
-2.175
-239.42%
67.48M
-69.46%
-1.965
+277.88%
38.93M
-58.61%
-2.180
-57.25%
Estimates Revision
The market is revising Downward the revenue expectations for GoHealth, Inc. (GOCO) for FY2025, with the revenue forecasts being adjusted by -32.29% over the past three months. During the same period, the stock price has changed by -38.88%.
Revenue Estimates for FY2025
Revise Downward
-32.29%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.16%
In Past 3 Month
Stock Price
Go Down
-38.88%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast GOCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOCO is 11.00 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.940
Low
10.00
Averages
11.00
High
12.00
Current: 2.940
Low
10.00
Averages
11.00
High
12.00
RBC Capital
Sector Perform
downgrade
$12 -> $5
2025-11-26
Reason
RBC Capital
Price Target
$12 -> $5
2025-11-26
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on GoHealth to $5 from $12 and keeps a Sector Perform rating on the shares. The firm is updating its model following the company's Q3 results, which came in significantly below expectations due to topline weakness as a result of one large carrier suspending its relationship with, the analyst tells investors in a research note.
William Blair
Outperform -> Market Perform
downgrade
2025-11-18
Reason
William Blair
Price Target
2025-11-18
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded GoHealth to Market Perform from Outperform.
William Blair
William Blair
Outperform -> Market Perform
downgrade
2025-11-18
Reason
William Blair
William Blair
Price Target
2025-11-18
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded GoHealth to Market Perform from Outperform. Q3 revenue and Medicare submissions were below the firm's expectations as the company pulled back on new enrollment growth, aligning with insurer actions to prioritize profitability and member retention over board member expansion, the analyst tells investors in a research note. The firm added that it believes the decision to limit cash burn is prudent given he challenging market dynamic, though it downgrades the shares given market headwinds that will likely persist through 2026,unccertatinty on GoHealth's ability to generate sustainable positive cash flow, and limited progress in diversifying its business model.
Noble Capital
Patrick McCann
Outperform
downgrade
$20 -> $10
2025-11-14
Reason
Noble Capital
Patrick McCann
Price Target
$20 -> $10
2025-11-14
downgrade
Outperform
Reason
Noble Capital analyst Patrick McCann lowered the firm's price target on GoHealth to $10 from $20 and keeps an Outperform rating on the shares. Q3 results came in below expectations and management expects the current environment to last several quarters as carriers recalibrate benefit structures and cost models, notes the analyst, whose Q4 and 2026 forecasts are now "materially lower than our previous estimates." However, the firm believes the long-term revenue and margin potential remain attractive once the Medicare Advantage market stabilizes, the analyst tells investors.
Noble Capital
Patrick McCann
Outperform
to
Outperform
downgrade
$25 -> $20
2025-08-08
Reason
Noble Capital
Patrick McCann
Price Target
$25 -> $20
2025-08-08
downgrade
Outperform
to
Outperform
Reason
Noble Capital analyst Patrick McCann lowered the firm's price target on GoHealth to $20 from $25 and keeps an Outperform rating on the shares after the company reported Q2 revenue below the firm's forecast. The firm now expects Q3 revenue to moderate to $100M, down from its prior estimate, and it trimmed both revenue and adjusted EBITDA estimates for 2025, but it continues to anticipate revenue growth and margin expansion in 2026.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Gohealth Inc (GOCO.O) is -0.36, compared to its 5-year average forward P/E of -17.40. For a more detailed relative valuation and DCF analysis to assess Gohealth Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-17.40
Current PE
-0.36
Overvalued PE
52.64
Undervalued PE
-87.45
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
10.33
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.85
Undervalued EV/EBITDA
2.80
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.28
Current PS
0.00
Overvalued PS
0.57
Undervalued PS
-0.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
GOCO News & Events
Events Timeline
(ET)
2025-11-13
07:08:17
GoHealth CEO emphasizes prioritizing 'quality over quantity'
2025-11-13
07:07:33
GoHealth Announces Q3 Earnings Per Share of $11.80 Compared to 46 Cents Last Year
2025-08-07 (ET)
2025-08-07
07:34:38
GoHealth reports Q2 EPS ($5.10) vs ($2.70) last year
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/54f8f76530f526335ffe5b572384adba26e8ad7f55d720ed32fc749b8ea773a1.jpg)
Preview
9.5
11-13NASDAQ.COMGoHealth (GOCO) Announces Q3 Loss, Falls Short of Revenue Projections
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/b9e9797ec03f18a61d8243fb34d9db3f514ead03590d974255a1dd83accc9f85.jpg)
Preview
2.0
09-22NASDAQ.COMBrighthouse Financial (BHF) Rises 27.2%: Is There More Growth Potential for the Stock?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/2b589e24dc058109bd00bacc94bb317fe9d78ff00d333f4796ecc89ae766e6ec.png)
Preview
2.0
08-24Benzinga5 Financial Stocks Face Challenges in Growth, Underperforming Compared to Sector Rivals
Sign Up For More News
People Also Watch
FAQ
What is Gohealth Inc (GOCO) stock price today?
What is Gohealth Inc (GOCO)'s business?
What is the price predicton of GOCO Stock?
What is Gohealth Inc (GOCO)'s revenue for the last quarter?
What is Gohealth Inc (GOCO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Gohealth Inc (GOCO)'s fundamentals?
How many employees does Gohealth Inc (GOCO). have?